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Abstract
Aims: Hypoglycemia is a severe side effect of intensive insulin therapy. Recurrent hypoglycemia (RH) impairs the counter-
regulatory response (CRR) which restores euglycemia. During hypoglycemia, ventromedial hypothalamus (VMH) production
of nitric oxide (NO) and activation of its receptor soluble guanylyl cyclase (sGC) are critical for the CRR. Hypoglycemia also
increases brain reactive oxygen species (ROS) production. NO production in the presence of ROS causes protein S-
nitrosylation. S-nitrosylation of sGC impairs its function and induces desensitization to NO. We hypothesized that during
hypoglycemia, the interaction between NO and ROS increases VMH sGC S-nitrosylation levels and impairs the CRR to
subsequent episodes of hypoglycemia. VMH ROS production and S-nitrosylation were quantified following three
consecutive daily episodes of insulin-hypoglycemia (RH model). The CRR was evaluated in rats in response to acute insulin-
induced hypoglycemia or via hypoglycemic-hyperinsulinemic clamps. Pretreatment with the anti-oxidant N-acetyl-cysteine
(NAC) was used to prevent increased VMH S-nitrosylation.
Results: Acute insulin-hypoglycemia increased VMH ROS levels by 4966.3%. RH increased VMH sGC S-nitrosylation.
Increasing VMH S-nitrosylation with intracerebroventricular injection of the nitrosylating agent S-nitroso-L-cysteine (CSNO)
was associated with decreased glucagon secretion during hypoglycemic clamp. Finally, in RH rats pre-treated with NAC
(0.5% in drinking water for 9 days) hypoglycemia-induced VMH ROS production was prevented and glucagon and
epinephrine production was not blunted in response to subsequent insulin-hypoglycemia.
Conclusion: These data suggest that NAC may be clinically useful in preventing impaired CRR in patients undergoing
intensive-insulin therapy.
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Introduction
Intensive insulin therapy is used clinically to obtain satisfactory
glycemic control in patients with both Type 1 (T1DM) and
advanced Type 2 diabetes mellitus (T2DM) in order to avoid long-
term complications of hyperglycemia. However, intensive insulin
therapy is limited by the induction of iatrogenic hypoglycemia.
Hypoglycemia is a profound threat to the brain since glucose is its
preferred fuel. In people without diabetes, a fall in blood glucose
level is detected both centrally and peripherally and triggers
appropriate protective mechanisms including the release of
hormones (e.g. glucagon, epinephrine) which stimulate endoge-
nous glucose production and reduce glucose tissue uptake. These
mechanisms known as the counter-regulatory response (CRR)
prevent and limit hypoglycemia and restore blood glucose level to
its physiological set point [1]. Unfortunately, in most patients with
diabetes treated with intensive insulin therapy, the CRR is
impaired as a consequence of recurrent episodes of hypoglycemia
(RH). This impairment is known as hypoglycemia-associated
autonomic failure (HAAF). During HAAF, the glycemic threshold
for CRR initiation shifts to lower glucose levels. Thus, glucose
levels are allowed to drop, without detection, to dangerously low
or lethal levels [1,2,3]. Although HAAF is the major limiting factor
in intensive insulin therapy, the cellular mechanisms involved in its
development remain unclear.
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In the brain, the ventromedial hypothalamus (VMH) plays a
critical role in the initiation of the CRR [4,5,6]. The VMH
contains specialized neurons which detect changes in extracellular
glucose level known as glucose sensing neurons (GSNs) [7,8,9,10].
Among the GSNs, we and others have suggested that glucose-
inhibited (GI) neurons, which are excited as glucose level falls, play
a major role in the CRR [7]. That is, we showed that the response
of VMH GI neurons to decreased glucose was impaired in
conditions where the CRR is also impaired such as after RH [11].
In addition, our laboratory showed that the gaseous messenger,
nitric oxide (NO) is required for both glucose sensing by GI
neurons and full initiation of the CRR [12,13]. Decreased glucose
activates AMP-activated protein kinase (AMPK) in GI neurons
leading to phosphorylation of neuronal nitric oxide synthase
(nNOS) and NO production. NO then binds to its cytosolic
receptor, soluble guanylyl cyclase (sGC) and increases the levels of
cyclic guanosine monophosphate (cGMP). Increased cGMP levels
are essential for full AMPK activation, chloride channel closure
and increased activity of GI neurons [13]. Disruption of any part
of the nNOS-NO-sGC signaling pathway impairs glucose sensing
by GI neurons and reduces the CRR [12,13,14]. In fact, mice
lacking nNOS have an impaired CRR and a complete absence of
GI neurons [12]. These data are consistent with a key role for NO
signaling in GI neurons in the initiation of the CRR.
While sGC mediates many of NO’s physiological effects
including the regulation of the CRR and glucose sensing in GI
neurons, NO also affects other signaling pathways through S-
nitrosylation. S-nitrosylation is a post-translational modification
consisting of the addition of a NO moiety to a free-thiol cysteine in
proteins [15]. S-nitrosylation alters the activity of proteins/
enzymes involved in glucose sensing. For instance, S-nitrosylation
of the sGC decreases its activity and affinity for NO [16]. S-
nitrosylation can occur in the presence of elevated levels of reactive
oxygen species (ROS) [15]. Insulin-induced hypoglycemia has
been suggested to increase hypothalamic ROS levels and decrease
anti-oxidant defenses in normal and diabetic rats [17]. Thus,
concomitant VMH NO and ROS production during insulin-
induced hypoglycemia may increase S-nitrosylation levels. In this
study, we hypothesize that VMH S-nitrosylation of proteins
involved in glucose sensing such as sGC contributes to the
mechanism(s) underlying the development of HAAF.
Materials and Methods
Animals
All procedures were approved by the Institutional Animal Care and
Use Committee at the University of Medicine and Dentistry of New
Jersey (Newark, NJ, USA) and the University of Burgundy (Dijon,
France; ROS measurement only). Adult male Sprague-Dawley rats
(100–150 g for in vivo experiments; 4–5 weeks old for in vitro imaging
experiment) were purchased from Charles Rivers. Animals were
housed individually and maintained on a 12–12 hour light–dark
schedule at 22–23uC with ad libitum access to standard chow and water.
RH protocol
Rats were assigned to four treatment groups as represented in
Table 1. Rats were either injected daily subcutaneously with saline
or insulin (4 U/kg; regular human; Lilly) for three consecutive
days. Using this established RH protocol we have already shown
that impaired CRR is associated with impaired sensitivity of VMH
Table 1. Representation of different treatment groups used.
Treatment Days
Day
1
Day
2
Day
3
Day
4
Groups S3 S Saline Saline Saline Saline
S3 I Saline Saline Saline Insulin
I3 S Insulin Insulin Insulin Saline
I3 I Insulin Insulin Insulin Insulin
Rats were injected daily with either saline or insulin (4 U/kg; subcutaneously)
for four consecutive days.
doi:10.1371/journal.pone.0068709.t001
Figure 1. Hypoglycemia increases VMH ROS production.
Quantification of fluorescence intensity of the ROS sensitive probe
H2DCFDA in VMH of rats treated daily subcutaneously with saline or
insulin (4 U/kg) for four consecutive days as presented in Table 1 (S3S:
n = 16; S3I: n = 12; I3S: n = 4; I3I: n = 5). *: p,0.05 S3S vs S3I (One-way
ANOVA followed by Bonferoni post-hoc test).
doi:10.1371/journal.pone.0068709.g001
Figure 2. RH increases VMH S-nitrosylation. (A) Representative
Western blot against VMH S-nitrosylated sGC (Upper panel), total sGC
(Middle panel) and b actin (Bottom panel) from S3S and I3S rats. The
lower band of the Upper panel represents the b-sGC subunit revealed
using an anti-biotin switch-assay following pull down with anti-b-sGC.
Since both a and b sGC subunits are known to be S-nitrosylated [16],
the top band is probably the a subunit which would have been pulled
down with the b subunit as an heterodimer with anti-b. (B) Relative S-
nitrosylated sGC quantification normalized to total protein content. *:
p,0.05 (n = 3; unpaired t-test).
doi:10.1371/journal.pone.0068709.g002
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GSNs to decreased glucose [11]. The fourth day, VMH ROS
production, S-nitrosylation or the CRR were analyzed in response
to an acute subcutaneous injection of saline (groups S3S and I3S)
or insulin (4 U/kg; groups S3I and I3I). Every day of the RH
protocol, food was removed for three hours from one hour before
the subcutaneous injection to two hours after.
N-acetyl-cysteine (NAC) treatment
NAC (Sigma) was prepared fresh daily and given in drinking
water (5 g/l) for 9 days prior and during the RH protocol. When
normalized to the amount of NAC at 5 g/l consumed per day, this
dose of NAC is equivalent to 536617 mg/day/kg of body weight.
This dose of NAC was chosen because it is equivalent to what it is
given in human medicine for treatment against paracetamol
intoxication per day [18]. It is noteworthy that NAC given at 5 g/l
in drinking water decreased fluid intake (water: 13662.7 vs NAC:
10763.4 ml/day/kg of body weight; n = 4; p,0.05). However,
even though NAC decreased water intake, NAC treatment did not
alter body weight gain during the treatment (body weight gain:
water treated rats: + 24.860.9 vs NAC treated rats: + 23.561.2 g).
This is consistent with other studies showing that given at a higher
dose does not affect body weight gain [19].
VMH ROS level measurement
VMH ROS levels were measured as previously described [20].
Briefly, the fourth day of the RH protocol, rats were injected with
saline (S3S or I3S) or insulin (S3I or I3I; 4 U/kg, subcutaneously)
and sacrificed 45 minutes later by decapitation. Brains were
quickly removed and the VMH harvested, snap frozen and stored
at 280uC. Tissue treatment for ROS determination was
performed according to Szabados et al. [21]. VMH chunks were
incubated with the fluorescent probe 2,7 dichlorodihydro-fluores-
cein diacetate (H2DCFDA; 4 mmol/l in 1 ml; Molecular Probes)
for 30 min at 37uC. After centrifugation (3000 g; 15 min; 4uC),
protein content was quantified on the pellet. ROS were measured
in 200 ml of supernatant using a Fluorescent Plate Reader (Perkin
Elmer) at 535 nm under excitation at 490 nm. Fluorescence
intensity was expressed as arbitrary units per milligram of protein.
VMH S-nitrosylation measurement
The fourth day of the RH protocol, rats were injected with
saline (S3S or I3S) and sacrificed 45 minutes later by decapitation.
VMH were harvested, snap frozen and stored at 280uC. S-
nitrosylation of soluble guanylyl cyclase (sGC) was determined
using an S-nitrosylated protein detection kit (Cayman Chemical
Company, Ann Arbor, MI) based on the method of Jaffrey et al.
[22]. Briefly, the VMH were lysed in the dark and proteins were
acetone precipitated. Free cysteine thiol groups were blocked
according to the instructions in the kit. Existing nitrosylated thiol
groups were then reduced to free thiols and labeled with biotin.
sGC was immunoprecipitated using an antibody agaisnt the beta
subunit of sGC (1:10, Cayman Chemical Company) and a
Western blot was performed against biotin (1:75, S-nitrosylation
detection kit, Cayman Chemical Company). Biotinylated thiols
were visualized using horse radish peroxidase and quantified using
Image J software against total protein content, which was quantified
by Coomassie Blue staining. Only lanes which contained equal
amounts of protein were used to determine the level of S-nitrosylation.
CRR monitoring in response to acute insulin injection
Five to seven days before the beginning of the RH protocol, rats
were anesthetized with sodium pentobarbital (50 mg/kg, IP,
Ovation) and surgically implanted with vascular catheters in the
right jugular vein. Catheters were filled with heparin (10 U/ml)
and flushed every other day. Animals were allowed 5–7 days to
recover from surgery before starting the RH protocol and were
handled every day. Animals that did not recover to their pre-
surgery body weights were excluded from the study. At the end of
the RH protocol, following the fourth injection of saline or insulin,
blood glucose was monitored every 15 minutes from 230 to
120 minutes post-insulin infusion via tail prick. Blood samples
(500 ml) taken from the jugular catheter at 0, 60 and 120 minutes
for subsequent measurement of plasma glucagon and epinephrine.
For glucagon, 250 ml of blood was collected in chilled tubes
containing EGTA (1.6 mg/ml, Sigma) and aprotinin (250 KIU,
Sigma). For catecholamines, blood was collected in chilled tubes
containing reduced glutathione (1.2 mg/ml, Sigma) and EDTA
(1.8 mg/ml, Sigma).
Hyperinsulinemic/hypoglycemic clamp
Rats were anesthetized with sodium pentobarbital (50 mg/kg,
IP, Ovation) and surgically implanted with vascular catheters in
the right jugular vein. Catheters were filled with heparin (10 U/
ml) and flushed every other day. Additionally, rats were
stereotaxically implanted with microinjection cannula guide in
the 3rd ventricle according to stereotaxic coordinates (from
bregma: 22.0 mm anterior-posterior, 0 mm medial-lateral, and
28.0 mm dorsal-ventral). Animals were allowed 5–7 days to
recover from surgery and were handled every day before
performing the hypoglycemic clamp. Animals that did not recover
to their pre-surgery body weights were excluded from the study.
The day of the experiment, food was removed for six hours before
the beginning of the clamp. Starting 60 minutes after ICV infusion
(CSNO or artificial cerebrospinal fluid (aCSF) containing (in mM):
126 NaCl, 1.9 KCl, 1.2 KH2PO4, 26 NaHCO3, 2.4 CaCl2, 1.3
MgCl2, 300 mOsM, pH 7.4), rats were injected through the
jugular catheter with an insulin bolus (rats: 0.4 U/kg) in order to
decrease glycemia to ,50 mg/dl within 30–40 minutes. This time
course was used based on the results of Saberi et al. suggesting that
brain vs peripheral glucose sensors predominate in CRR initiation
when blood glucose decreases rapidly [23]. After this bolus,
animals were perfused with insulin at 1.2 U/kg/h for 90 minutes.
Glucose (20%) was co-perfused with insulin in order to maintain
their plasma glucose level around 45–50 mg/dl. The concentra-
tion of blood glucose was measured every 10 minutes via tail prick.
Blood samples (500 ml) taken from the jugular catheter were
collected as described above at 0 and 90 minutes for subsequent
measurement of plasma glucagon, epinephrine and norepineph-
rine. At the end of each experiment, cannula placement was
verified by methyl-blue injection (Sigma).
Plasma glucagon and catecholamines determination
Plasma glucagon concentrations were determined using com-
mercially available radio-immunoassay kits (Linco Research).
Plasma epinephrine and norepinephrine concentrations were
analyzed by high-performance liquid chromatography using
electrochemical detection (ESA, Acton).
Measurement of membrane potential using fluorescence
imaging plate reader membrane potential dye (FLIPR-
MPD)
VMH dissociated neurons were prepared as previously
described [13]. Neurons were visualized on an Olympus BX61
WI microscope with a610 objective equipped with a red filter for
fluorometric imaging plate reader membrane potential dye
(FLIPR-MPD) visualization (excitation, 548 nm; emission, 610–
VMH S-Nitrosylation and CRR Impairment
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675 nm). Incubation of VMH neurons in extracellular solution
(composition in mM: 25 HEPES, 121 NaCl, 4.7 KCl, 1.2 MgSO4,
5 NaHCO3, 2 CaCl2, 0.23 KH2PO4, 0.97 K2HPO4, and
2.5 glucose, pH 7.4) containing FLIPR-MPD (1 vial/667 mL
extracellular solution) at 34uC began 30 min before and continued
throughout the duration of all experiments. Images were acquired
and analyzed with MetaMorph software (Universal Imaging) at
30-second intervals over the course of each experiment using a
charge-coupled device camera (Cool Snap HQ; Photometrics) as
extracellular glucose level was changed from 2.5 to 0.7 mM. The
fluorescence intensity of each image (expressed as gray scale units
per pixel) was normalized to that of the co-incubated fluorescent
beads. Neurons which have a reversible increase in fluorescence of
12% or greater compared to that observed in 2.5 mM glucose are
considered to be GI. An average percent change of .12% in
FLIPR-MPD fluorescence intensity between 25 and 30 min
[%DFLIPR-MPD (25–30)] defined a depolarized neuron. This
threshold was defined as exceeding twice standard deviation of
fluorescence variation observed with no glucose change (i.e. noise).
Cell viability was confirmed at the end of each experiment by a 5-
min exposure to 25 mM KCl. The percentage of depolarized
neurons [%DFLIPR-MPD (25–30) .12%] in response to 2.5–
0.7 mM glucose decrease per culture dish was recorded for each
rat treatment groups.
Data analysis
All data are presented as mean 6 SEM. Statistical analysis was
performed using Graphpad Prism 5.0 by two-way ANOVA or
one-way ANOVA followed by Dunnett or Bonferoni post-hoc test
or by paired or unpaired t-test as described in the figure legends.
p,0.05 indicates statistical significance.
Results
Insulin-hypoglycemia increases the level of VMH ROS
production
Singh et al. previously showed that insulin-induced hypoglyce-
mia decreases the level of diencephalic antioxidant proteins
catalase and glutathione (GSH) and increases the level of lipid
peroxidation [17]. These data suggest that hypoglycemia increases
hypothalamic ROS levels. In order to confirm these findings, we
quantified the fluorescence intensity level of the ROS sensitive
probe H2DCFDA (29,79-dichlorodihydrofluorescein diacetate) in
the VMH of rats exposed to single or recurrent episodes of insulin-
hypoglycemia. Rat treatment groups are represented in Table 1.
As shown in Figure 1, the level of H2DCFDA fluorescence
intensity was significantly increased by a factor of 1.560.6 in
response to a single episode of insulin-hypoglycemia (Figure 1).
Surprisingly, the basal VMH ROS level was not altered after
recurrent episodes of insulin-hypoglycemia. Furthermore, a fourth
episode of insulin-hypoglycemia failed to increase VMH ROS
production (Figure 1). Together, these data are consistent with
increased VMH ROS production after a single episode of
hypoglycemia.
RH increases the level of VMH S-nitrosylation
We previously showed that insulin-hypoglycemia increases
VMH NO production [12]. In the presence of elevated ROS
levels, NO may interact with the reactive free-thiol cysteine in
proteins to create a covalent modification, S-nitrosylation (SNO)
[15]. The NO receptor sGC, which we have shown to be involved
in CRR regulation, is a known target of S-nitrosylation [12,16,24].
Figure 3. ICV CSNO injection increases VMH sGC S-nitrosylation and impairs the CRR. (A) Representative Western blot against VMH S-
nitrosylated sGC from control and CSNO treated rats. (B–C) Blood glucose level (B left panel; n = 9; Inset: average blood glucose during the last
30 minutes of the clamp); glucose infusion rate (GIR; B right panel; n = 9; Inset: AUC of the GIR during the last 30 minutes of the clamp); plasma
glucagon (C upper left panel; n = 5), epinephrine (C lower left; n = 5) and norepinephrine levels (C lower right panel; n = 5) during hyperinsulinemic/
hypoglycemic clamp (1.2 U/kg/h) of animals injected ICV with aCSF (Control) or CSNO (0.5 mM). *: p,0.05 vs controls (Two-way ANOVA followed by
Bonferoni post-hoc test); $: p,0.05 vs control (unpaired t-test); ¤: p,0.05 time 0 vs time 90 (paired t-test); NS: p.0.05 time 0 vs time 90 (paired t-test).
doi:10.1371/journal.pone.0068709.g003
Figure 4. NAC treatment prevents hypoglycemia-induced
increased VMH ROS production. Quantification of VMH fluores-
cence intensity of the ROS sensitive probe H2DCFDA of rats injected SC
with saline or insulin (4 U/kg) and treated or not with NAC (5 g/l) in
their drinking water. Data are expressed as % of control rats not treated
with NAC and injected with saline (S3S). n number: S3S: n = 16; S3S +
NAC: n = 8; S3I + NAC: n = 8. NS: p.0.05 (One-way ANOVA).
doi:10.1371/journal.pone.0068709.g004
Figure 5. NAC prevents increased VMH S-nitrosylation after
RH. Representative western blot against VMH S-nitrosylated sGC (Top)
or total sGC (Bottom) from control (S3S) and RH rats (I3S) pre-treated or
not with NAC. The lower band of the Upper panel represents the b-sGC
subunit revealed using an anti-biotin switch-assay following pull down
with anti- b-sGC. The top band is probably the a subunit which would
have been pulled down with the b subunit as an heterodimer with anti-
b.
doi:10.1371/journal.pone.0068709.g005
VMH S-Nitrosylation and CRR Impairment
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To test our main hypothesis that the level of S-nitrosylation is
increased after RH, we quantified the level of S-nitrosylated sGC
in the VMH. Our data show that RH increased the basal level of
S-nitrosylated sGC by a factor of 4.360.34 (n = 3; Figure 2A, B)
where total VMH sGC level was not affected by RH (S3S:
1.0460.04 vs I3S: 1.04660.06 AU total sGC/b actin; n = 3; p
.0.05, unpaired t-test; Figure 2A).
Figure 6. NAC prevents the impaired CRR following RH. Blood glucose levels (first top panel), plasma glucagon (second panel), epinephrine
(third panel) and norepinephrine levels (lower panel) in response to insulin-hypoglycemia in control (A) and NAC pre-treated (B) rats following 3
consecutive daily injections of either insulin (S3I) or saline (I3I). *: p,0.05 S3I vs I3I (Repeated measures Two-way ANOVA followed by Bonferoni post-
hoc test within control and NAC pre-treated rats).
doi:10.1371/journal.pone.0068709.g006
VMH S-Nitrosylation and CRR Impairment
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Increased VMH S-nitrosylation impairs the CRR
We hypothesized that increased VMH S-nitrosylation is
involved in CRR impairment after RH. To determine whether
increased VMH S-nitrosylation is associated with an impaired
CRR, we injected rats with the NO donor and nitrosylating agent
S-nitroso-L-cysteine (CSNO; 0.5 mM) intracerebroventricularly
(ICV) in the third ventricle and analyzed the CRR using a
hyperinsulinemic/hypoglycemic clamp. First, as expected, ICV
CSNO injection increased the level of VMH S-nitrosylated sGC
(Figure 3A). Following ICV CSNO injection, the glucose infusion
rate (GIR) necessary to maintain the blood glucose level around
45 mg/dl was significantly increased during the last 30 minutes of
the clamp (Figure 3B). This increase in the GIR was associated
with reduced glucagon secretion. In control animals, 90 min after
the beginning of the clamp, plasma glucagon, epinephrine and
norepinephrine levels were significantly increased (Figure 3C).
CSNO injection did not alter plasma epinephrine and norepi-
nephrine release. However, in CSNO treated rats, plasma
glucagon level was not significantly increased during the hyper-
insulinemic/hypoglycemic clamp, unlike control (Figure 3C).
These data suggest that increased VMH S-nitrosylation is
associated with CRR impairment.
NAC pre-treatment prevents VMH S-nitrosylation and
impaired CRR after RH
We hypothesized that RH-induced VMH sGC S-nitrosylation
and CRR impairment is the consequence of concomitant ROS
and NO production. Thus, prevention of ROS production during
hypoglycemia should attenuate or prevent S-nitrosylation and the
impaired CRR. To test this hypothesis, we treated rats with N-
acetyl-cysteine (NAC) in their drinking water (0.5%) for 9 days
prior to and during RH and analyzed the level of VMH S-
nitrosylation and the CRR. NAC treatment did not affect basal
VMH ROS level (Figure 4). However, while insulin-hypoglycemia
increased VMH ROS production by 50% in control rats (Figure 1),
insulin-hypoglycemia did not significantly increase VMH ROS
levels in NAC treated rats (Figure 4). Furthermore, NAC pre-
treatment significantly decreased the level of VMH sGC S-
nitrosylation following RH (I3S: 1.8660.15 vs I3S + NAC:
0.6960.15 AU/total protein content; n = 3; unpaired t-test;
p,0.05; Figure 5) without affecting total sGC level. Finally, as
shown in Figure 6, NAC pre-treatment prevented CRR impair-
ment following RH. In control animals, blood glucose levels of rats
exposed to RH fell further and glucagon and epinephrine
production were blunted in response to a fourth episode of
insulin-hypoglycemia (I3I) as compared to saline-injected rats
exposed to one episode of hypoglycemia (S3I). A trend toward
decreased plasma norepinephrine levels was also observed after
RH in I3I animals (Figure 6A). However, following NAC pre-
treatment there were no significant differences between the blood
glucose decline or glucagon and epinephrine production in rats
exposed to a single (S3I) or recurrent (I3I) episodes of insulin-
hypoglycemia. In addition, plasma norepineprhine levels were
increased after RH in I3I animals treated with NAC (Figure 6B).
Thus, NAC prevents RH-induced VMH S-nitrosylation and CRR
impairment.
NAC pre-treatment prevents impaired VMH GI neuronal
response to decreased glucose after RH
We previously showed that the glucose response of VMH GI
neurons to decreased glucose is impaired after RH [11]. We
confirm these data using membrane potential sensitive imaging in
cultured VMH neurons which quantifies the number of VMH GI
neurons observed in response to a 2.5–0.7 mM glucose decrease
(Figure 7). The number of VMH GI neurons was significantly
decreased by 37.567.78% after RH. Interestingly, while NAC
pre-treatment did not alter the number of VMH GI neurons in
naı¨ve rats, NAC prevented the decreased number of VMH GI
neurons after RH (Figure 7B).
Discussion
We hypothesized in the present study that increased VMH S-
nitrosylation of key glucose sensing proteins such as sGC after RH
may impair the CRR to subsequent hypoglycemia. Our data show
that VMH sGC S-nitrosylation is indeed increased after RH
where the CRR is impaired. Interestingly, we found that ICV
CSNO increases VMH sGC S-nitrosylation and also impairs the
CRR. Finally, pre-treating rats with the antioxidant NAC prevents
increased VMH sGC S-nitrosylation, impaired glucose sensing by
GI neurons and the blunted CRR following RH. Thus, our study
supports the hypothesis that preventing increased VMH sGC S-
nitrosylation may prevent glucose sensing and CRR impairment
following RH.
We previously showed that hypoglycemia-induced VMH NO
production plays a critical role in the CRR through a sGC
dependent mechanism [12]. In addition to its sGC-dependent
Figure 7. NAC prevents VMH GI neuron activation by
decreased glucose. (A) Representative fluorescence intensity mea-
surement from FLIPR-MD recording of a VMH GI (black full line) and a
non-glucose sensitive neuron (gray dotted line). The black dotted line
represents the fluorescence intensity baseline. Glucose concentration
changes and KCl application are schematically displayed above each
recording. (B) Percentage of VMH GI neurons from S3S or I3S rats pre-
treated or not with NAC which depolarized in response to a 2.5–0.7 mM
glucose decrease quantified using changes in FLIPR-MPD fluorescence
intensity. *: p,0.05 (Two-way ANOVA; group differences were
determined by One-Way ANOVA followed by Bonferoni post-hoc test).
doi:10.1371/journal.pone.0068709.g007
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signaling pathway, NO affects other signaling pathways through S-
nitrosylation. S-nitrosylation is a non-enzymatic reaction consist-
ing of the covalent attachment of a NO moiety to the thiol side
chain of cysteine to form SNO adducts, altering the properties of
proteins/enzymes [15,25]. It is noteworthy that the NO bond is
labile which makes S-nitrosylation difficult to detect and quantify.
Nevertheless, over the past decade, the number of reported
substrates for S-nitrosylation has grown significantly [22]. This is
consistent with the ubiquity of reactive-site thiols across protein
classes. sGC is one of the many target proteins of S-nitrosylation
[16]. We found herein that VMH sGC S-nitrosylation is increased
after RH, a condition where the CRR is impaired. The fact that
the NO donor and nitrosylating agent CSNO increases VMH
sGC S-nitrosylation and impairs the CRR further support the idea
that increased VMH S-nitrosylation plays a critical role in CRR
impairment. However, CSNO may also interact with side chain of
tyrosine to create tyrosine nitration [26]. Thus, we cannot exclude
that tyrosine nitration might also be involved in CSNO-induced
CRR impairment and more generally in the development of
HAAF.
The current findings support our hypothesis that VMH GI
neurons control the CRR through a NO-sGC dependent pathway
[11,12,13]. We have found that the response of VMH GI neurons
to decreased glucose is impaired in a number of conditions where
the CRR is impaired [11,12,27,28]. For example, electrophysio-
logical evaluation of VMH GI neurons in brain slices from rats
after RH showed that the threshold to activate VMH GI neurons
shifts to lower glucose levels. We now extend these results by
evaluating the glucose sensitivity of isolated VMH GI neurons
from rats after RH with and without NAC treatment using the
FLIPR-MPD imaging technique. The FLIPR-MPD technique is
not sensitive enough to quantify the absolute degree of depolar-
ization in response to a specific glucose decrease. Rather, we are
only able to detect the percentage of VMH neurons which
depolarize over a noise threshold. In the present study, fewer
VMH neurons from RH treated rats depolarized in response to
decreased glucose. Thus, we interpret the present results to mean
that fewer VMH GI neurons depolarized over the FLIPR-MPD
depolarization threshold as glucose decreased rather than an
actual decrease in the number of VMH GI neurons. Importantly,
NAC prevents RH-induced impairment of both the CRR and
glucose sensing by VMH GI neurons. These data provide further
support for a role of VMH GI neurons in regulating the CRR.
The mechanism underlying RH-induced increased VMH S-
nitrosylation remains a question of interest. Increased NO
production via the inducible NOS (iNOS) has been shown to
increase S-nitrosylation levels [29]. However, we previously
showed that iNOS activity is not altered in response to either
acute or recurrent hypoglycemia [12,30]. S-nitrosylation may also
occur when NO is produced under oxidative conditions where
NO and ROS can interact [31]. In support of this hypothesis, we
found that hypoglycemia increases both VMH ROS and NO
levels [30]. Increased VMH ROS level during hypoglycemia is
consistent with a previous study showing that hypoglycemia
decreased expression of antioxidant factors and increased lipid
peroxidation [17]. To further support the hypothesis that VMH
ROS production is involved in hypoglycemia-induced increased S-
nitrosylation levels, we found that treating rats with the
antioxidant NAC prevents both increased VMH ROS and S-
nitrosylation levels. NAC, as a precursor for glutathione biosyn-
thesis is a very powerful antioxidant that also reacts directly with
electrophiles [19]. NAC is used in vitro and in vivo to decrease ROS
and S-nitrosylation levels [16,24,32]. In human or animal models
NAC is used to prevent and reverse negative clinical outcomes
such as nitrate tolerance and paracetamol overdose [33,34].
Surprisingly, NAC treatment did not decrease basal VMH ROS
level as one might have expected. It is possible that while NAC
treatment at the dose of 5 g/l (,0.55 g/kg/day) was not sufficient
to alter basal cell redox status, this dose was able to prevent any
small increase in ROS production. This idea is consistent with the
study from Kamboj et al. showing that NAC given at 1.5 g/kg/day
in the drinking water did not alter basal glutathione or lipid
peroxidation levels in control rats [19]. In addition, our data
suggest that VMH ROS production does not play a role in CRR
initiation under basal conditions. That is, while NAC pre-
treatment inhibited hypoglycemia-induced VMH ROS produc-
tion, it did not affect CRR hormones secretion in response to a
single episode of hypoglycemia. In contrast, blood glucose level did
fall further in response to insulin-hypoglycemia in NAC-treated
rats. This is consistent with Song et al.’s study showing that NAC
increases insulin sensitivity in an animal model of T2DM [35].
Thus, the lower glucose nadir observed in non-RH NAC treated
rats is likely due to an increased sensitivity to insulin injection.
The next point which needs to be addressed is the mechanism
involved in hypoglycemia-induced VMH ROS production. VMH
ROS formation may be consequent to increased NO production.
In support of this, NO inhibits mitochondrial cytochrome c and
blocks mitochondrial respiration which consequently increases
superoxide anion O2
N2 production [36]. Increased NO production
during hypoglycemia also activates the neuronal NAPDH oxidase
which could, in turn, increase ROS through a mitochondria-
independent pathway [37]. On the other hand, the amount of NO
produced by nNOS is relatively low when compared to that
produced by iNOS. This suggests that these NO-dependent
mechanisms may not be the only cause of increased ROS levels. In
support of this, lipid peroxidation, an indirect marker of ROS
production, is increased in response to insulin-hypoglycemia in the
cortex [17]. However, we did not observe increased cortical NO
release following insulin-hypoglycemia [12]. Decreased antioxi-
dant defenses may also explain increased ROS levels. Hypogly-
cemia is associated with decreased activity of the antioxidant
enzymes catalase and super oxide dismutase [17]. In addition,
insulin is also known to increase VMH ROS production [38].
Thus, insulin injection used in our clinically relevant model of
hypoglycemia may also contribute to the increased VMH ROS
production. Further studies are clearly needed to determine which
mechanism(s) underlie insulin-hypoglycemia-induced ROS pro-
duction.
Furthermore, we do not yet understand why increased VMH S-
nitrosylation persists after RH when neither VMH NO nor ROS
levels remain elevated. Recently, it was suggested that protein S-
nitrosylation is more stable than initially thought, and is mainly
dependent upon a dynamic denitrosylation process such as that
regulated by the thioredoxin system [39,40]. As such, we can infer
that, once induced, protein S-nitrosylation lasts for a certain
period of time in the absence of nitrosylating agents (NO, ROS)
and/or if thioredoxin reducing ability is impaired. Thus, following
a transitory burst of ROS and NO production in response to a
single episode of insulin-hypoglycemia, VMH S-nitrosylation level
remains increased for some time. It is well established that the
CRR remains impaired for approximately 2 weeks following RH,
after which a normal CRR is restored if there have been no further
hypoglycemic episodes during that time [3]. We speculate that the
persistent increase in VMH S-nitrosylation could play a role in the
development of the sustained CRR impairment after RH at least
in the initial phase. It is possible that elevated protein nitrosylation
and/or reduced NO signaling leads to downstream changes in
other intracellular signaling pathways which explain the duration
VMH S-Nitrosylation and CRR Impairment
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of HAAF. However, further studies of the correlation between the
duration of HAAF, VMH S-nitrosylation and the signaling
pathways involved are needed to support or refute this hypothesis.
In addition, the question whether RH-induced increased S-
nitrosylation is specific to the VMH remains. Increased S-
nitrosylation may happen in brain areas not known to be involved
in the regulation of the CRR such as the cortex. However, even
though ROS production is increased in the cortex in response to
hypoglycemia, we previously showed that NO production is not
[12,17]. Further studies are still needed to determine whether S-
nitrosylation is increased in extra-hypothalamic regions after RH.
The most important finding of our study is that NAC pre-
treatment prevents both increased VMH S-nitrosylation, de-
creased number of VMH GI neurons and blunted glucagon and
epinephrine secretion in response to RH. While the present study
does not establish a direct causal link between increased VMH S-
nitrosylation and CRR impairment, when considered in the
context of our previous work, our data strengthen our hypothesis
that VMH S-nitrosylation plays an important role in the impaired
CRR following RH. That is, we have shown that inhibiting the
NO-sGC pathway specifically in the VMH impairs the CRR [12].
Since S-nitrosylation of sGC causes NO resistance, VMH S-
nitrosylation would certainly impair NO-sGC signaling and as a
result impair the CRR. However, since NAC was administered
orally, we cannot exclude VMH S-nitrosylation independent
effects in the prevention of CRR impairment. Nevertheless, our
study suggests that NAC might be an important clinical therapy
for the treatment of HAAF. The dose of NAC used in drinking
water (0.5%) corresponds approximately to 0.55 g/kg/day based
on the rats’ water intake. This dose of NAC is equivalent to that
used clinically in humans to reverse the liver damage following
paracetamol intoxication [18]. This is particularly relevant since
NAC is approved for use in humans in the US as well as in
Europe. As mentioned above, the insulin dose for patients with T1
or T2DM using insulin therapy would have to be carefully
monitored when initiating NAC therapy since NAC increases
insulin sensitivity [35]. This is especially true since our study only
evaluated NAC as a prophylactic therapy given before hypogly-
cemia occurred. Additional studies need to be performed to
determine whether NAC can be used as a treatment to reverse
HAAF following RH. However, since improving insulin sensitivity
would allow patients to reduce their insulin doses, prophylactic
NAC therapy may be very efficacious for patients with T1 or
T2DM both in terms of preventing HAAF and improving overall
health.
In conclusion, our study shows that increased VMH ROS
production may contribute to the development of HAAF following
RH. Moreover, the mechanism by which ROS exerts its
deleterious effects on the CRR may involve S-nitrosylation of
key proteins involved in hypothalamic glucose sensing (e.g., sGC).
This study also shows that preventing S-nitrosylation with NAC
may be useful for patients with T1 or advanced T2DM treated
with insulin therapy. Since NAC is already FDA approved for use
in humans, our study highlights an exciting new therapy which
could be rapidly adapted to treat HAAF in patients with T1 or
advanced T2DM.
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